Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

bba02a9cbd247726a421640582239f48d8d0d6af02232b667c568f4441d2c973

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from Debt [USD, Millions]

Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

77b78e7a4da7fd68d15c7bbc5cb7a141d61f2de3e2900a7236807c295e5c436a

United States

Europe

Western Hemisphere

Western Hemisphere, excluding U.S.

Asia-Pacific, Africa

Total Revenue

617673f9904fd6a9f3a425f2e3cf03a624c16de65c05377cf5f349b9dde9b0c0

1ab0679ca87b12295b5472f0cd92b17c64472c573beda00cde4e933ca8fc7fdd

Net impact of acquisitions and divestitures on worldwide operational sales growth (percentage)

Net impact of acquisitions and divestitures on Innovative Medicine segment operational sales growth (percentage)

Net impact of acquisitions and divestitures on U.S. operational sales growth (percentage)

Net impact of acquisitions and divestitures on international operational sales growth (percentage)

Net impact of acquisitions and divestitures on MedTech segment operational sales growth (percentage)

Impact of the Covid-19 Vaccine sales decline on worldwide operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on Innovative Medicine segment operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on international Innovative Medicine operational sales (percentage)

Impact of the Covid-19 Vaccine sales decline on the European region operational sales (percentage)

7e7cab8423d58ce1312f5b7d3c638d179a2e2a48ce8cac7a24c0d9523869d2a0

Sales to customers (USD, millions)

Cost of products sold (USD, millions)

Gross profit (USD, millions)

Selling, marketing and administrative expenses (USD, millions)

Research and development expense (USD, millions)

Interest expense, net of portion capitalized (USD, millions)

Other (income) expense, net (USD, millions)

Restructuring (USD, millions)

Earnings before provision for taxes on income (USD, millions)

Provision for taxes on income (USD, millions)

Net earnings (USD, millions)

fdad81677a175a8d8f907317dc182f4a6e1e7f579141e8de11f26f95516b1978

Free Cash Flow (USD, millions)

0f6524534a4c170d80bbadbeff5a6c8b4a7e00b381e1f08ffb29b0b4de12f096

6ca92877cd6c127ebd1870890853bdf2f664f6206eb89fa7d22d6da07726cbd2

Cash and Cash Equivalents (USD, millions)

Total Current Assets (USD, millions)

Total Assets (USD, millions)

Total Current Liabilities (USD, millions)

Total Liabilities (USD, millions)

Total Shareholders’ Equity (USD, millions)

afdd7527dd711005b37e570cd4670f837bb4208ab5d69887701d10643cab25f3

Johnson & Johnson (JNJ)

Financials